IceCure Medical Announces Strategic Deal With Terumo

Get Instant Instagram Followers and Likes with GetInsta

GetInsta App is 100% safe and secure to get benefits from online smart feature plans. There are lots of reliable and smart feature explorations to achieve your objectives. Learn more!

Philips Introduces Integrated Interventional Hemodynamic System with Patient Monitor IntelliVue X3

The integration provides the opportunity for monitoring during image-guided procedures on the Philips Image Guided Therapy System – Azurion, improving workflow with comprehensive patient records that support timely clinical decision-making during interventional cardiology procedures and beyond.

Lawson Health Research Institute Found Simple Device Improves Care After Kidney Transplantation

The geko™ device, manufactured by Sky Medical Technology Ltd and distributed in Canada by Trudell Healthcare Solutions Inc., is a muscle pump activator that significantly improves blood flow by stimulating the body’s ‘muscle pumps.’

IceCure Medical Ltd. is a developer of the next generation cryoablation technology to treat malignant and benign tumors by freezing without the need for surgery. Today the company announced they entered into an exclusive distribution agreement with leading global medical company, Terumo Corporation (Tokyo: 4543, TRUMY: OTC US). The new agreement will accelerate the commercialization of its ProSense™ cryoablation system and associated consumables to treat malignant breast tumors in Japan and Singapore.

  • Under the terms of the agreement, in exchange for granting exclusive distribution rights and obtaining regulatory approvals for ProSense™ and its consumables, Terumo will commit up to USD $2 million. This will include a one-time, up-front payment of USD $1 million to IceCure 30-days after signing the agreement and the remainder in milestones.
  • The agreement also comprises Terumo’s undertaking to purchase 10 ProSense™ system consoles and consumables at the time of signing for use in clinical trials to support regulatory filing.
  • Terumo will also be responsible for, and incur costs for, obtaining all regulatory approvals and insurance indemnifications in Japan, with regulatory rights owned by Terumo.  Initial regulatory approval is anticipated in Japan in a few years.

Eyal Shamir, IceCure’s CEO, stated, “We are excited to partner with Terumo, a leading global medical company, in this milestone agreement. With Terumo’s proven medical distribution network and the necessary sales and marketing expertise, this new partnership will support rapid commercialization of our cryoablation solution in Japan and Singapore, pending regulatory approval.”

“The ProSense™ system has already demonstrated excellent progress as a rapid, in-office solution for the treatment of breast tumors.  With its expanding clinical data as a non-surgical alternative to treat cancer, the innovative ProSense™ system makes an exciting addition to our portfolio to address key unmet needs and improve patient outcomes,” said Tsuyoshi Tomita, Group Manager, General Hospital Products Group, Terumo Corporation.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles